Aspira Women's Health
Biotechnology ResearchView the employees at
Aspira Women's Health-
Chelsea LaValle Staff Accountant at Aspira Women's Health
-
New York City Metropolitan Area
-
Rising Star
Ryan Phan Health & Life Science Executive-
Palo Alto, California, United States
-
Top 5%
Vanessa Falk Supervisor at Aspira Women's Health-
Cheshire, Connecticut, United States
-
Rising Star
Kristina Lancaster tech at Vermillion, Inc.-
Wichita, Kansas, United States
-
Rising Star
Kelly Ennis Director Financial Planning Analysis at Vermillion, Inc-
Trumbull, Connecticut, United States
-
Rising Star
Overview
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.
-